Journal
BIOMARKERS IN MEDICINE
Volume -, Issue -, Pages -Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/bmm-2023-0034
Keywords
acute kidney injury; aortic stenosis; biomarker ratio; cardiorenal syndrome; hepcidin; NT-proBNP; TAVI
Categories
Ask authors/readers for more resources
This study aimed to determine whether novel and conventional cardiorenal biomarkers in patients before transcatheter aortic valve implantation may be associated with cardiorenal syndrome (CRS) type 1. Serum NT-proBNP and urine biomarkers (hepcidin-25, NGAL, IL-6) were measured, and it was found that patients with CRS type 1 had longer hospital stay and had higher readmission rate within 6 months after discharge. The NT-proBNP/urine hepcidin-25 ratio was identified as an independent modifier of CRS type 1.
Background: This study aimed to determine whether novel and conventional cardiorenal biomarkers in patients before transcatheter aortic valve implantation may be associated with cardiorenal syndrome (CRS) type 1. Methods: Serum NT-proBNP and urine biomarkers (hepcidin-25, NGAL, IL-6) were measured before and 24 h after transcatheter aortic valve implantation. Results: 16/95 patients had CRS type 1. Those patients had longer length of stay in hospital (12.5 [9.0-16.0] vs 9.0 [8-12] days; p = 0.025) and were more frequently readmitted to hospital within 6 months after discharge (46.7 vs 15.6%; odds ratio: 4.7; 95% CI: 1.5-15.5; p = 0.007). The NT-proBNP/urine hepcidin-25 ratio (odds ratio: 2.89; 95% CI: 1.30-6.41; p = 0.009) was an independent modifier of CRS type 1. Conclusion: The NT-proBNP/urine hepcidin-25 ratio appears to be a modifier of risk of CRS type 1.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available